| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDE9A |
| Uniprot No | O76083-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-533aa |
| 氨基酸序列 | MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCIATGLPRNTT ISLLTTDDAMVSIDPTMPANSERTPYKVRPVAIKQLSEREELIQSVLAQV AEQFSRAFKINELKAEVANHLAVLEKRVELEGLKVVEIEKCKSDIKKMRE ELAARSSRTNCPCKYSFLDNHKKLTPRRDVPTYPKYLLSPETIEALRKPT FDVWLWEPNEMLSCLEHMYHDLGLVRDFSINPVTLRRWLFCVHDNYRNNP FHNFRHCFCVAQMMYSMVWLCSLQEKFSQTDILILMTAAICHDLDHPGYN NTYQINARTELAVRYNDISPLENHHCAVAFQILAEPECNIFSNIPPDGFK QIRQGMITLILATDMARHAEIMDSFKEKMENFDYSNEEHMTLLKMILIKC CDISNEVRPMEVAEPWVDCLLEEYFMQSDREKSEGLPVAPFMDRDKVTKA TAQIGFIKFVLIPMFETVTKLFPMVEEIMLQPLWESRDRYEELKRIDDAM KELQKKTDSLTSGATEKSRERSRDVKNSEGDCA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PDE9A重组蛋白的3篇代表性文献及其摘要内容：
---
1. **文献名称**: *"Expression, purification, and characterization of human phosphodiesterase 9A (PDE9A)"*
**作者**: Wang H. et al.
**摘要**: 该研究描述了人源PDE9A的重组表达与纯化方法，利用杆状病毒-昆虫细胞系统成功获得高纯度蛋白。通过酶动力学分析，证实其特异性水解cGMP的活性，为后续抑制剂筛选提供了基础。
---
2. **文献名称**: *"Crystal structure of phosphodiesterase 9A in complex with a selective inhibitor"*
**作者**: Hu J. et al.
**摘要**: 本研究解析了PDE9A重组蛋白与选择性小分子抑制剂的复合物晶体结构，揭示了其催化结构域的结合位点特征，为靶向PDE9A的药物设计提供了结构生物学依据。
---
3. **文献名称**: *"Functional characterization of PDE9A isoforms in cGMP signaling pathways"*
**作者**: Hetman K. et al.
**摘要**: 通过重组表达不同剪接变体PDE9A蛋白，比较了各亚型在cGMP水解效率和组织分布上的差异，发现特定亚型在脑组织中高表达，提示其与神经退行性疾病的潜在关联。
---
**备注**：上述文献为示例性质，实际引用时需核实数据库(如PubMed)中的具体信息。研究多聚焦于PDE9A的重组表达、结构解析及与疾病相关的功能机制。
**Background of PDE9A Recombinant Protein**
Phosphodiesterase 9A (PDE9A) is a member of the phosphodiesterase (PDE) enzyme family, which plays a critical role in regulating intracellular cyclic nucleotide signaling by hydrolyzing cyclic guanosine monophosphate (cGMP). Unlike other PDEs, PDE9A exhibits high specificity for cGMP, making it a key modulator of pathways dependent on this secondary messenger. It is widely expressed in human tissues, including the central nervous system, kidneys, heart, and immune cells, suggesting diverse physiological roles in cognition, cardiovascular function, and inflammation.
Recombinant PDE9A protein is engineered through molecular cloning and expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional enzymes for research and drug discovery. Its recombinant form retains catalytic activity, enabling studies on enzyme kinetics, inhibitor screening, and structural analysis. PDE9A’s relevance to disease has driven significant interest, particularly in neurodegenerative disorders like Alzheimer’s disease, where cGMP signaling deficits are implicated in cognitive decline. Preclinical studies highlight that PDE9A inhibition enhances cGMP levels, potentially improving synaptic plasticity and memory.
Structurally, PDE9A contains a conserved catalytic domain and unique regulatory regions, which recombinant proteins help characterize. X-ray crystallography using recombinant PDE9A has revealed binding sites for inhibitors, guiding rational drug design. Several PDE9A-targeting compounds have entered clinical trials for neurological and cardiovascular conditions.
Beyond therapeutics, recombinant PDE9A serves as a tool to investigate cGMP-dependent pathways in cellular models or assess biomarker potential in diseases. However, challenges remain in understanding isoform-specific functions and optimizing inhibitors for clinical use. Continued research with recombinant PDE9A is vital to unravel its biology and advance therapies for PDE9A-associated disorders.
(Word count: 249)
×
